Dick Heinegård (Former)
61 – 70 of 181
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2008
-
Mark
COMP a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker
(
- Contribution to journal › Article
-
Mark
The matrix PROLINE/Arginine-Rich end leucin-rich repeat protein (PRELP) impairs osteoclastogenesis by inhibiting NF-kappaB activity
(
- Contribution to journal › Published meeting abstract
-
Mark
Small leucine-rich repeat proteins of the extracellular matrix interact with the central core of complement inhibitor C4BP
(
- Contribution to journal › Published meeting abstract
-
Mark
The matrix proline/arginine-rich end leucine-rich repeat protein (PRELP) inhibits osteoclastogenesis inactivating NF-kappaB signal (Abstracts of the 35th European Symposium on Calcified Tissues)
2008) 35th European Symposium on Calcified Tissues In Calcified Tissue International 82(Suppl. 1). p.33-33(
- Contribution to journal › Published meeting abstract
-
Mark
The role of histidine rich glycoprotein in the modulation of immune function
(
- Contribution to journal › Published meeting abstract
-
Mark
Purification, crystallization and preliminary X-ray diffraction analysis of human chondroadherin.
2008) In Acta Crystallographica. Section F: Structural Biology and Crystallization Communications 64(Pt 6). p.516-519(
- Contribution to journal › Article
- 2007
-
Mark
Reduced cell proliferation and increased apoptosis are significant pathological mechanisms in a murine model of mild pseudoachondroplasia resulting from a mutation in the C-terminal domain of COMP
(
- Contribution to journal › Article
-
Mark
Aging enhances a mechanically-induced reduction in tendon strength by an active process involving matrix metalloproteinase activity
(
- Contribution to journal › Article
-
Mark
Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials
(
- Contribution to journal › Article
-
Mark
Fragmentation of proteins in cartilage treated with IL-1. Specific cleavage of type IX collagen by MMP-13 releases the NC4 domain.
(
- Contribution to journal › Article